Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
$18.41
-$0.41(-3.60%)
At close: 4:00 PM EST
$18.41
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$8.73 - $18.96
Previous CloseN/A
Volume1.46M
Average Volume (3M)8.63M
Market Cap
$12.57B
Enterprise Value$3.73B
Total Cash (Recent Filing)$4.50B
Total Debt (Recent Filing)$99.69M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 10, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding682,881,700
10 Day Avg. Volume8,848,508
30 Day Avg. Volume8,634,246
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue160.61
Enterprise Value/Gross Profit177.70
Enterprise Value/Ebitda-3.80
Forecast
1Y Price Target
$21.44Price Target Upside16.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Commercial PotentialBrepocitinib is expected to become the first targeted therapy for dermatomyositis by 2027, with anticipated peak sales of ~$1B, raising the price target to $20/share.
Market ExpansionBrepo's market share in dermatomyositis can expand beyond where off-label JAK inhibitors are today.
Product DifferentiationThe robust Phase 3 VALOR data of brepocitinib in dermatomyositis shows fast and durable improvement across broad disease symptoms, enhancing its appeal.
Bears Say
Efficacy ComparisonThe primary efficacy of brepocitinib came in modestly below pipeline competitors.
Safety ConcernsRoivant expects brepo to carry class-related label safety warning.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.73 and its highest was $18.95 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $12.57B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Nov 10, 2025 which is in 11 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Aug 11, 2025. The company reported -$0.252 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.002.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.32.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 682,881,700 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.252 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -2.785%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.44 (16.46% Upside)
$21.44 (16.46% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 10.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.48%
12-Months-Change
Fundamentals
Return on Equity
-15.84%
Trailing 12-Months
Asset Growth
-22.53%
Trailing 12-Months
Company Description
Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$21.44
▲(16.46% Upside)
Technical Analysis
Ownership Overview
20.72% Insiders
13.65% Mutual Funds
0.03% Other Institutional Investors
52.72% Public Companies and
Individual Investors